Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice

Journal of Lipid Research

Volumn 49, Issue 1, 2008, Pages 217-229

  MacDonald, Marcia L E ^a   Singaraja, Roshni R ^a   Bissada, Nagat ^a   Ruddle, Piers ^a   Watts, Russell ^b   Karasinska, Joanna M ^a   Gibson, William T ^a   Fievet, Catherine ^c,d,e   Vance, Jean E ^b   Staels, Bart ^c,d,e   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c INSTITUT PASTEUR DE LILLE   (France)

^d INSERM   (France)

^e UNIV LILLE   (France)

Author keywords

Apolipoprotein B; Atherosclerosis; ATP binding cassette transporter A1; Coenzyme A; High density lipoprotein; Hyperlipidemia; Liver; Low density lipoprotein receptor; Monounsaturated fatty acids; Mouse model; Very low density lipoprotein; Western diet

Indexed keywords

ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE 1; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL DIET; CONTROLLED STUDY; FEMALE; GLUCOSE TOLERANCE TEST; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT GAIN;

ADIPOSITY; ANIMALS; BODY WEIGHT; CELLS, CULTURED; DIET; FATTY LIVER; HEPATOCYTES; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; METABOLIC SYNDROME X; MICE; MICE, MUTANT STRAINS; RECEPTORS, LDL; STEAROYL-COA DESATURASE;

EID: 38049169032     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700478-JLR200     Document Type: Article

References (95)

1. Alberti, K. G., and P. Z. Zimmet. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 15: 539-553.
2. Isomaa, B. 2003. A major health hazard: the metabolic syndrome. Life Sci. 73: 2395-2411.
3. Grundy, S. M. 2002. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 105: 2696-2698.
4. Miyazaki, M., and J. M. Ntambi. 2003. Role of stearoyl-coenzyme A desaturase in lipid metabolism. Prostaglandins Leukot. Essent. Fatty Acids. 68: 113-121.
5. Ntambi, J. M. 1999. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J. Lipid Res. 40: 1549-1558.
6. Miyazaki, M., Y. C. Kim, M. P. Gray-Keller, A. D. Attie, and J. M. Ntambi. 2000. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J. Biol. Chem. 275: 30132-30138.
7. Zhang, L., L. Ge, S. Parimoo, K. Stenn, and S. M. Prouty. 1999. Human stearoyl-CoA desaturase: alternative transcripts generated from a single gene by usage of tandem polyadenylation sites. Biochem. J. 340: 255-264.
8. Ntambi, J. M., S. A. Buhrow, K. H. Kaestner, R. J. Christy, E. Sibley, T. J. J. Kelly, and M. D. Lane. 1988. Differentiation-induced gene expression in 3T3-L1 preadipocytes. Characterization of a differentially expressed gene encoding stearoyl-CoA desaturase. J. Biol. Chem. 263: 17291-17300.
9. Kaestner, K. H., J. M. Ntambi, T. J. J. Kelly, and M. D. Lane. 1989. Differentiation-induced gene expression in 3T3-L1 preadipocytes. A second differentially expressed gene encoding stearoyl-CoA desaturase. J. Biol. Chem. 264: 14755-14761.
10. Zheng, Y., S. M. Prouty, A. Harmon, J. P. Sundberg, K. S. Stenn, and S. Parimoo. 2001. Scd3 - a novel gene of the stearoyl-CoA desaturase family with restricted expression in skin. Genomics. 71: 182-191.
11. Miyazaki, M., M. J. Jacobson, W. C. Man, P. Cohen, E. Asilmaz, J. M. Friedman, and J. M. Ntambi. 2003. Identification and characterization of murine SCD4, a novel heart-specific stearoyl-CoA desaturase isoform regulated by leptin and dietary factors. J. Biol. Chem. 278: 33904-33911.
12. Beiraghi, S., M. Zhou, C. B. Talmadge, N. Went-Sumegi, J. R. Davis, D. Huang, H. Saal, T. A. Seemayer, and J. Sumegi. 2003. Identification and characterization of a novel gene disrupted by a pericentric inversion inv(4)(p13.1q21.1) in a family with cleft lip. Gene. 309: 11-21.
13. Zhang, S., Y. Yang, and Y. Shi. 2005. Characterization of human SCD2, an oligomeric desaturase with improved stability and enzyme activity by cross-linking in intact cells. Biochem. J. 388: 135-142.
14. Wang, J., L. Yu, R. E. Schmidt, C. Su, X. Huang, K. Gould, and G. Cao. 2005. Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates. Biochem. Biophys. Res. Commun. 332: 735-742.
15. Bené, H., D. Lasky, and J. M. Ntambi. 2001. Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. Biochem. Biophys. Res. Commun. 284: 1194-1198.
16. Hulver, M. W., J. R. Berggren, M. J. Carper, M. Miyazaki, J. M. Ntambi, E. P. Hoffman, J. P. Thyfault, R. Stevens, G. L. Dohm, J. A. Houmard, et al. 2005. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab. 2: 251-261.
17. Riserus, U., G. D. Tan, B. A. Fielding, M. J. Neville, J. Currie, D. B. Savage, V. K. Chatterjee, K. N. Frayn, S. O'Rahilly, and F. Karpe. 2005. Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Diabetes. 54: 1379-1384.
18. Corpeleijn, E., E. Feskens, E. Jansen, M. Mensink, W. Saris, T. de Bruin, and E. Blaak. 2006. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia. 49: 2392-2401.
19. Stumvoll, M. 2004. Control of glycaemia: from molecules to men. Minkowski Lecture 2003. Diabetologia. 47: 770-781.
20. Lovejoy, J. C., C. M. Champagne, S. R. Smith, J. P. DeLany, G. A. Bray, M. Lefevre, Y. M. Denkins, and J. C. Rood. 2001. Relationship of dietary fat and serum cholesterol ester and phospholipid fatty acids to markers of insulin resistance in men and women with a range of glucose tolerance. Metabolism. 50: 86-92.
21. Antonini, F. M., A. Bucalossi, E. Petruzzi, R. Simoni, P. L. Morini, and A. D'Alessandro. 1970. Fatty acid composition of adipose tissue in normal, atherosclerotic and diabetic subjects. Atherosclerosis. 11: 279-289.
22. Warensjo, E., U. Riserus, and B. Vessby. 2005. Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia. 48: 1999-2005.
23. Warensjo, E., M. Ohrvall, and B. Vessby. 2006. Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women. Nutr. Metab. Cardiovasc. Dis. 16: 128-136.
24. Pan, D. A., S. Lillioja, M. R. Milner, A. D. Kriketos, L. A. Baur, C. Bogardus, and L. H. Storlien. 1995. Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J. Clin. Invest. 96: 2802-2808.
25. Simon, J. A., J. Fong, and J. T. J. Bernert. 1996. Serum fatty acids and blood pressure. Hypertension. 27: 303-307.
26. Chu, K., M. Miyazaki, W. C. Man, and J. M. Ntambi. 2006. Stearoylcoenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol. Cell. Biol. 26: 6786-6798.
27. Wilkinson, D. I., and M. A. Karasek. 1966. Skin lipids of a normal and mutant (asebic) mouse strain. J. Invest. Dermatol. 47: 449-455.
28. Zheng, Y., K. J. Eilertsen, L. Ge, L. Zhang, J. P. Sundberg, S. M. Prouty, K. S. Stenn, and S. Parimoo. 1999. Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse. Nat. Genet. 23: 268-270.
29. Sundberg, J. P., D. Boggess, B. A. Sundberg, K. Eilertsen, S. Parimoo, M. Filippi, and K. Stenn. 2000. Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. Am. J. Pathol. 156: 2067-2075.
30. Lu, Y., L. Bu, S. Zhou, M. Jin, J. P. Sundberg, H. Jiang, M. Qian, Y. Shi, G. Zhao, X. Kong, et al. 2004. Scd1ab-Xyk: a new asebia allele characterized by a CCC trinucleotide insertion in exon 5 of the stearoyl-CoA desaturase 1 gene in mouse. Mol. Genet. Genomics. 272: 129-137.
31. Georgel, P., K. Crozat, X. Lauth, E. Makrantonaki, H. Seltmann, S. Sovath, K. Hoebe, X. Du, S. Rutschmann, Z. Jiang, et al. 2005. A Toll-like receptor 2-responsive lipid effector pathway protects mammals against skin infections with Gram-positive bacteria. Infect. Immun. 73: 4512-4521.
32. Miyazaki, M., W. C. Man, and J. M. Ntambi. 2001. Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. J. Nutr. 131: 2260-2268.
33. Binczek, E., B. Jenke, B. Holz, R. H. Günter, M. Thevis, and W. Stoffel. 2007. Obesity resistance of the stearoyl-CoA desaturase-deficient (scd1(-/-)) mouse results from disruption of the epidermal lipid barrier and adaptive thermoregulation. Biol. Chem. 388: 405-418.
34. Ntambi, J. M., M. Miyazaki, J. P. Stoehr, H. Lan, C. M. Kendziorski, B. S. Yandell, Y. Song, P. Cohen, J. M. Friedman, and A. D. Attie. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl. Acad. Sci. USA. 99: 11482-11486.
35. Cohen, P., M. Miyazaki, N. D. Socci, A. Hagge-Greenberg, W. Liedtke, A. A. Soukas, R. Sharma, L. C. Hudgins, J. M. Ntambi, and J. M. Friedman. 2002. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science. 297: 240-243.
36. Terasaka, N., A. Hiroshima, T. Koieyama, N. Ubukata, Y. Morikawa, D. Nakai, and T. Inaba. 2003. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536: 6-11.
37. Levin, N., E. D. Bischoff, C. L. Daige, D. Thomas, C. T. Vu, R. A. Heyman, R. K. Tangirala, and I. G. Schulman. 2005. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25: 135-142.
38. Hobbs, H. H., M. S. Brown, and J. L. Goldstein. 1992. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1: 445-466.
39. Rana, J. S., A. C. Jansen, A. H. Zwinderman, M. Nieuwdorp, E. S. van Aalst-Cohen, J. W. Jukema, M. D. Trip, and J. J. P. Kastelein. 2006. Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia. Diabetes Care. 29: 1125-1127.
40. Hill, J. S., M. R. Hayden, J. Frohlich, and P. H. Pritchard. 1991. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler. Thromb. 11: 290-297.
41. Ferrières, J., J. Lambert, S. Lussier-Cacan, and J. Davignon. 1995. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor genemutation. Circulation. 92: 290-295.
42. Junyent, M., M. Cofán, I. Núñez, R. Gilabert, D. Zambón, and E. Ros. 2006. Influence of HDL cholesterol on preclinical carotid atherosclerosis in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 26: 1107-1113.
43. Hirobe, K., Y. Matsuzawa, K. Ishikawa, S. Tarui, A. Yamamoto, S. Nambu, and K. Fujimoto. 1982. Coronary artery disease in heterozygous familial hypercholesterolemia. Atherosclerosis. 44: 201-210.
44. Real, J. T., F. J. Chaves, I. Martínez-Usó, A. B. García-García, J. F. Ascaso, and R. Carmena. 2001. Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur. Heart J. 22: 465-471.
45. Yanagi, K., S. Yamashita, S. Kihara, T. Nakamura, S. Nozaki, Y. Nagai, T. Funahashi, K. Kameda-Takemura, Y. Ueyama, S. Jiao, et al. 1997. Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis. 132: 43-51.
46. Vuorio, A. F., H. Turtola, K. M. Piilahti, P. Repo, T. Kanninen, and K. Kontula. 1997. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler. Thromb. Vasc. Biol. 17: 3127-3138.
47. Gaudet, D., M. C. Vohl, P. Perron, G. Tremblay, C. Gagné, D. Lesiège, J. Bergeron, S. Moorjani, and J. P. Després. 1998. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation. 97: 871-877.
48. Getz, G. S., and C. A. Reardon. 2006. Diet and murine atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26: 242-249.
49. Schreyer, S. A., C. Vick, T. C. Lystig, P. Mystkowski, and R. C. LeBoeuf. 2002. LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am. J. Physiol. Endocrinol. Metab. 282: E207-E214.
50. Reardon, C. A., L. Blachowicz, J. Lukens, M. Nissenbaum, and G. S. Getz. 2003. Genetic background selectively influences innominate artery atherosclerosis: immune system deficiency as a probe. Arterioscler. Thromb. Vasc. Biol. 23: 1449-1454.
51. Towler, D. A., M. Bidder, T. Latifi, T. Coleman, and C. F. Semenkovich. 1998. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J. Biol. Chem. 273: 30427-30434.
52. Merat, S., F. Casanada, M. Sutphin, W. Palinski, and P. D. Reaven. 1999. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler. Thromb. Vasc. Biol. 19: 1223-1230.
53. Coenen, K. R., M. L. Gruen, A. Chait, and A. H. Hasty. 2007. Diet-induced increases in adiposity, but not plasma lipids, promote macrophage infiltration into white adipose tissue. Diabetes. 56: 564-573.
54. Miyazaki, M., Y. C. Kim, and J. M. Ntambi. 2001. A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J. Lipid Res. 42: 1018-1024.
55. Attie, A. D., R. M. Krauss, M. P. Gray-Keller, A. Brownlie, M. Miyazaki, J. J. Kastelein, A. J. Lusis, A. F. Stalenhoef, J. P. Stoehr, M. R. Hayden, et al. 2002. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J. Lipid Res. 43: 1899-1907.
56. Kang, K., M. Miyazaki, J. M. Ntambi, and M. W. Pariza. 2004. Evidence that the anti-obesity effect of conjugated linoleic acid is independent of effects on stearoyl-CoA desaturase1 expression and enzyme activity. Biochem. Biophys. Res. Commun. 315: 532-537.
57. Miyazaki, M., A. Dobrzyn, W. C. Man, K. Chu, H. Sampath, H. Kim, and J. M. Ntambi. 2004. Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms. J. Biol. Chem. 279: 25164-25171.
58. Miyazaki, M., A. Dobrzyn, H. Sampath, S. Lee, W. C. Man, K. Chu, J. M. Peters, F. J. Gonzalez, and J. M. Ntambi. 2004. Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptoralpha. J. Biol. Chem. 279: 35017-35024.
59. Ishibashi, S., M. S. Brown, J. L. Goldstein, R. D. Gerard, R. E. Hammer, and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92: 883-893.
60. Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, S. Wang, M. Thoolen, D. J. Mangelsdorf, et al. 2000. Role of LXRs in control of lipogenesis. Genes Dev. 14: 2831-2838.
61. Kunnecke, B., P. Verry, A. Benardeau, and M. von Kienlin. 2004. Quantitative body composition analysis in awake mice and rats by magnetic resonance relaxometry. Obes. Res. 12: 1604-1615.
62. Tailleux, A., M. Bouly, G. Luc, G. Castro, J. M. Caillaud, N. Hennuyer, P. Poulain, J. C. Fruchart, N. Duverger, and C. Fievet. 2000. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice. Arterioscler. Thromb. Vasc. Biol. 20: 2453-2458.
63. Singaraja, R. R., C. Fievet, G. Castro, E. R. James, N. Hennuyer, S. M. Clee, N. Bissada, J. C. Choy, J. C. Fruchart, B. M. McManus, et al. 2002. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest. 110: 35-42.
64. Kulinski, A., and J. E. Vance. 2007. Lipid homeostasis and lipoprotein secretion in Niemann-Pick C1-deficient hepatocytes. J. Biol. Chem. 282: 1627-1637.
65. Wellington, C. L., E. K. Y. Walker, A. Suarez, A. Kwok, N. Bissada, R. Singaraja, Y. Yang, L. Zhang, E. James, J. E. Wilson, et al. 2002. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab. Invest. 82: 273-283.
66. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
67. R Development Core Team. 2006. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
68. Khan-Merchant, N., M. Penumetcha, O. Meilhac, and S. Parthasarathy. 2002. Oxidized fatty acids promote atherosclerosis only in the presence of dietary cholesterol in low-density lipoprotein receptor knockout mice. J. Nutr. 132: 3256-3262.
69. Wakil, S. J. 1989. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry. 28: 4523-4530.
70. Wakil, S. J., J. K. Stoops, and V. C. Joshi. 1983. Fatty acid synthesis and its regulation. Annu. Rev. Biochem. 52: 537-579.
71. Horton, J. D., J. L. Goldstein, and M. S. Brown. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109: 1125-1131.
72. Lee, G. H., R. Proenca, J. M. Montez, K. M. Carroll, J. G. Darvishzadeh, J. I. Lee, and J. M. Friedman. 1996. Abnormal splicing of the leptin receptor in diabetic mice. Nature. 379: 632-635.
73. Pratley, R. E. 1998. Gene-environment interactions in the pathogenesis of type 2 diabetes mellitus: lessons learned from the Pima Indians. Proc. Nutr. Soc. 57: 175-181.
74. Leiter, E. H. 1989. The genetics of diabetes susceptibility in mice. FASEB J. 3: 2231-2241.
75. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA. 99: 7604-7609.
76. Clee, S. M., J. J. Kastelein, M. van Dam, M. Marcil, K. Roomp, K. Y. Zwarts, J. A. Collins, R. Roelants, N. Tamasawa, T. Stulc, et al. 2000. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J. Clin. Invest. 106: 1263-1270.
77. Wellington, C. L., Y. Yang, S. Zhou, S. M. Clee, B. Tan, K. Hirano, K. Zwarts, A. Kwok, A. Gelfer, M. Marcil, et al. 2002. Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. J. Lipid Res. 43: 1939-1949.
78. Dobrzyn, A., P. Dobrzyn, M. Miyazaki, H. Sampath, K. Chu, and J. M. Ntambi. 2005. Stearoyl-CoA desaturase 1 deficiency increases CTP:choline cytidylyltransferase translocation into the membrane and enhances phosphatidylcholine synthesis in liver. J. Biol. Chem. 280: 23356-23362.
79. Wanless, I. R., and J. S. Lentz. 1990. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 12: 1106-1110.
80. Loria, P., A. Lonardo, and N. Carulli. 2005. Should nonalcoholic fatty liver disease be renamed? Dig. Dis. 23: 72-82.
81. Marchesini, G., M. Brizi, A. M. Morselli-Labate, G. Bianchi, E. Bugianesi, A. J. McCullough, G. Forlani, and N. Melchionda. 1999. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107: 450-455.
82. Samuel, V. T., Z. Liu, X. Qu, B. D. Elder, S. Bilz, D. Befroy, A. J. Romanelli, and G. I. Shulman. 2004. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279: 32345-32353.
83. Cai, D., M. Yuan, D. F. Frantz, P. A. Melendez, L. Hansen, J. Lee, and S. E. Shoelson. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11: 183-190.
84. Shoelson, S. E., L. Herrero, and A. Naaz. 2007. Obesity, inflammation, and insulin resistance. Gastroenterology. 132: 2169-2180.
85. Schmitz-Peiffer, C., D. L. Craig, and T. J. Biden. 1999. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J. Biol. Chem. 274: 24202-24210.
86. Chavez, J. A., T. A. Knotts, L. Wang, G. Li, R. T. Dobrowsky, G. L. Florant, and S. A. Summers. 2003. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J. Biol. Chem. 278: 10297-10303.
87. Voss, M. D., A. Beha, N. Tennagels, G. Tschank, A. W. Herling, M. Quint, M. Gerl, C. Metz-Weidmann, G. Haun, and M. Korn. 2005. Gene expression profiling in skeletal muscle of Zucker diabetic fatty rats: implications for a role of stearoyl-CoA desaturase 1 in insulin resistance. Diabetologia. 48: 2622-2630.
88. Sampath, H., M. Miyazaki, A. Dobrzyn, and J. Ntambi. 2007. Stearoyl CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat. J. Biol. Chem. 282: 2483-2493.
89. Flowers, J. B., M. E. Rabaglia, K. L. Schueler, M. T. Flowers, H. Lan, M. P. Keller, J. M. Ntambi, and A. D. Attie. 2007. Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice. Diabetes. 56: 1228-1239.
90. Dobrzyn, P., A. Dobrzyn, M. Miyazaki, P. Cohen, E. Asilmaz, D. G. Hardie, J. M. Friedman, and J. M. Ntambi. 2004. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl. Acad. Sci. USA. 101: 6409-6414.
91. Sun, Y., M. Hao, Y. Luo, C. P. Liang, D. L. Silver, C. Cheng, F. R. Maxfield, and A. R. Tall. 2003. Stearoyl-CoA desaturase inhibits ATP-binding cassette transporter A1-mediated cholesterol efflux and modulates membrane domain structure. J. Biol. Chem. 278: 5813-5820.
92. Wang, Y., and J. F. Oram. 2002. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J. Biol. Chem. 277: 5692-5697.
93. Uehara, Y., T. Engel, Z. Li, C. Goepfert, S. Rust, X. Zhou, C. Langer, C. Schachtrup, J. Wiekowski, S. Lorkowski, et al. 2002. Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes. 51: 2922-2928.
94. Wang, Y., B. Kurdi-Haidar, and J. F. Oram. 2004. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J. Lipid Res. 45: 972-980.
95. Flowers, M., A. Groen, O. A. Tebon, M. Keller, Y. Choi, K. Schueler, O. Richards, H. Lan, M. Miyazaki, F. Kuipers, et al. 2006. Cholestasis and hypercholesterolemia in SCD1-deficient mice fed a low-fat, high-carbohydrate diet. J. Lipid Res. 47: 2668-2680.